Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taspoglutide vs Exenatide in Type 2 Diabetes Mellitus (T-emerge 4)
NCT00717457Phase 3
Key facts
- Status
- Completed
- Start
- Jul 2008
- Primary completion
- Mar 2011
- Countries
- 26
- Sponsor
- Roche
- Modality
- Peptides
- Drugs
- taspoglutide
- Conditions
- type 2 diabetes mellitus (T2DM)
01
Overview
Phase 3, randomised, open-label trial of taspoglutide in type 2 diabetes mellitus (T2DM), sponsored by Roche. Started Jul 2008; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
This 3-arm study will assess the efficacy, safety and tolerability of taspoglutide compared with exenatide in patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both. Patients will be randomized to receive taspoglutide (10mg once weekly or 10mg once weekly for 4 weeks followed by 20mg once weekly) or exenatide (5 micrograms twice daily for 4 weeks followed by 10 micrograms twice daily) in a ratio of 1:1:1 in addition to continued prestudy metformin and thiazolidinedione either alone or in combination. The anticipated time on…
Beyond the preview
Go deeper on NCT00717457.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00717457.